Merck & Co., Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Davis
- Full Time Employees
- 73,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 126 East Lincoln Avenue Rahway NJ United States of America 07065
- IPO Date
- Jan 13, 1978
- CIK
- 0000310158
- Website
- merck.com
- Similar Companies
- Business
- Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a leading research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and animal health products worldwide; key human health offerings include oncology drugs such as Keytruda (pembrolizumab), the PD-1 inhibitor generating $29.5 billion in 2024 revenues for various cancers, Lynparza (olaparib), a PARP inhibitor for BRCA-mutated ovarian cancer, vaccines like Gardasil (HPV vaccine, $8.6 billion in 2024 revenues), ProQuad/M-M-R II/Varivax (MMRV combination vaccine, $2.5 billion in 2024 revenues), and additional products including Cancidas (caspofungin acetate) antifungal, Januvia/Janumet for diabetes, and veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals. Headquartered in Rahway, New Jersey, and founded over 130 years ago, the company operates globally across human health and animal health segments, targeting patients, healthcare providers, and animal health customers in major markets including the United States, Europe, Asia, and emerging regions. Recent developments include a November 2025 research and development funding agreement with Blackstone Life Sciences for $700 million to advance sacituzumab tirumotecan (sac-TMT), an investigational TROP2-targeted antibody-drug conjugate in 15 Phase 3 trials for breast, endometrial, and lung cancers; multiyear manufacturing expansions totaling nearly $6 billion across North Carolina, Delaware, Kansas, and Virginia to boost vaccine, biologic, and Keytruda production capacity as part of a broader $70 billion U.S. investment commitment; and a launched $3 billion restructuring plan emphasizing productivity savings and U.S.-based R&D and manufacturing enhancements.
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study
Bank of America Sees Interest Rates Exploding Higher Soon: Play It Safe With 4 Dividend Giants
AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?
Merck's Oncology Engine Is Still Accelerating
Merck's bowel disease drug meets main goal in late-stage trial
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens
Merck's pneumococcal vaccine wins US approval for high-risk children, teens
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention
Protillion Biosciences Announces Drug Discovery Collaboration with Merck
Merck: Buy The Dip On This Dividend Growth Pharma Leader
3 Dividend Stocks to Hold for the Long Haul
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines